Tissue engineering for muscles.
Tissue engineering in the news again this time its creating scaffolds for muscle regeneration.
Read more
“Bankers will become dinosaurs.” #AI article from The Guardian. https://www.theguardian.com/technology/2016/dec/22/bridgewat…management #Transhumanism
The company is already highly data-driven, with meetings recorded and staff asked to grade each other throughout the day using a ratings system called “dots”. The Systematized Intelligence Lab has built a tool that incorporates these ratings into “Baseball Cards” that show employees’ strengths and weaknesses. Another app, dubbed The Contract, gets staff to set goals they want to achieve and then tracks how effectively they follow through.
These tools are early applications of PriOS, the over-arching management software that Dalio wants to make three-quarters of all management decisions within five years. The kinds of decisions PriOS could make include finding the right staff for particular job openings and ranking opposing perspectives from multiple team members when there’s a disagreement about how to proceed.
The machine will make the decisions, according to a set of principles laid out by Dalio about the company vision.
And, who said we didn’t have motion pictures with color and sound together before 1931!
Believed to be the first ever, or at least oldest surviving, film produced with both color and sound. The color was made by hand-painting the individual frames of originally black & white film. The sound came from an accompaniment of a sound-on-cylinder recording of Benoit Constant Coquelin’s voice reciting one of Cyrano’s speeches.
Cyrano de Bergerac is a play written in 1897 by Edmond Rostand. Although there was a real Cyrano de Bergerac, the play is a fictionalization of his life that follows the broad outlines of it.
A few end of year thoughts on why the incoming Trump Administration should make a crewed lunar return its first priority.
A few reasons why the incoming Trump Administration should make a crewed return to the Moon its first space priority. NASA astronauts should once again trod the regolith.
Read more
Of all the potentially apocalyptic technologies scientists have come up with in recent years, the gene drive is easily one of the most terrifying. A gene drive is a tool that allows scientists to use genetic engineering to override natural selection during reproduction. In theory, scientists could use it to alter the genetic makeup of an entire species—or even wipe that species out. It’s not hard to imagine how a slip-up in the lab could lead to things going very, very wrong.
Read more
Rejuvenating the immune system offers hope for Alzheimer’s patients and removal of plaques.
Alzheimer′s disease (AD) is characterized by deposition of amyloid plaques, neurofibrillary tangles, and neuroinflammation. In order to study microglial contribution to amyloid plaque phagocytosis, we developed a novel ex vivo model by co‐culturing organotypic brain slices from up to 20‐month‐old, amyloid‐bearing AD mouse model (APPPS1) and young, neonatal wild‐type (WT) mice. Surprisingly, co‐culturing resulted in proliferation, recruitment, and clustering of old microglial cells around amyloid plaques and clearance of the plaque halo. Depletion of either old or young microglial cells prevented amyloid plaque clearance, indicating a synergistic effect of both populations. Exposing old microglial cells to conditioned media of young microglia or addition of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) was sufficient to induce microglial proliferation and reduce amyloid plaque size. Our data suggest that microglial dysfunction in AD may be reversible and their phagocytic ability can be modulated to limit amyloid accumulation. This novel ex vivo model provides a valuable system for identification, screening, and testing of compounds aimed to therapeutically reinforce microglial phagocytosis.
Read more
Non-profit research ultimately benefits for-profit companies and is an essential part of the development chain of any therapy.
Companies like Unity Biotech have taken non-profit research and are developing it for-profit, this is the only way that therapies will make it to market and pay for the huge costs involved in development. You may have concerns that our current crowdfunding project is with a for-profit company so here is CellAge to answer this question.
Their campaign can be found at Lifespan.io here: